Order Article Reprints

Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers. 2024; 16(15):2669. https://doi.org/10.3390/cancers16152669

Peisen, Felix, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas K. Eigentler, Teresa Amaral, Jan H. Moltz, and Ahmed E. Othman. 2024. "Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?" Cancers 16, no. 15: 2669. https://doi.org/10.3390/cancers16152669

Peisen, F., Gerken, A., Hering, A., Dahm, I., Nikolaou, K., Gatidis, S., Eigentler, T. K., Amaral, T., Moltz, J. H., & Othman, A. E. (2024). Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers, 16(15), 2669. https://doi.org/10.3390/cancers16152669